搜索
Cue Biopharma Inc
CUE添加自选
23.010USD
-2.320-9.16%
收盘 05/15, 16:00（美东）报价延迟15分钟
93.09M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-9.16%
5天
-34.26%
1月
+26.53%
6月
+33.62%
今年开始到现在
+151.15%
1年
+5.81%
TradingKey Cue Biopharma Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
Cue Biopharma Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名51/382位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价115.00。中期看，股价处于上升通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Cue Biopharma Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Cue Biopharma Inc亮点
亮点风险
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
业绩高增长
公司营业收入稳步增长，连续3年增长400.29%
业绩增长期
公司处于发展阶段，最新年度总收入27.47M美元
估值高估
公司最新PE估值-0.64，处于3年历史高位
机构减仓
最新机构持股21.86M股，环比减少3.75%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值238.35K
活跃度降低
近期活跃度降低，过去20天平均换手率1.39
分析师目标
根据
1
位分析师
买入
评级
115.000
目标均价
+399.78%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Cue Biopharma Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Cue Biopharma Inc简介
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
公司代码CUE
公司Cue Biopharma Inc
CEOAzam (Usman)
网址https://www.cuebiopharma.com/
相关品种
